IP Library Patent Application 13213471
Patent Application
App. No. 13/213,471

TOPICAL SKIN TREATMENT KITS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/213,471
Abstract

This invention relates to benzoyl peroxide products for skin treatment, and more particularly to a kit containing a benzoyl peroxide product and a topical moisturizing product. In one embodiment the kit contains BenzaClin® brand clindamycin-benzoyl peroxide gel and Viscontour® brand hyaluronic acid serum.

Claims (22)

1 . A kit comprising separate containers of a topical medication comprising benzoyl peroxide in a pharmaceutically acceptable carrier and a hydrating agent.

2 . The kit of claim 1 wherein the topical medication also contains an antibiotic.

3 . The kit of claim 2 wherein the antibiotic is clindamycin or a pharmaceutically acceptable salt or ester thereof.

4 . The kit of claim 3 wherein the topical medication comprises about 0.01 to about 10 weight percent antibiotic and about 0.1 to about 30 weight percent benzoyl peroxide.

5 . The kit of claim 4 wherein the antibiotic is clindamycin phosphate.

6 . The kit of claim 5 wherein the topical medication comprises about 1 weight percent clindamycin phosphate and about 5 weight percent benzoyl peroxide.

7 . The kit of claim 1 wherein the hydrating agent comprises a hyaluronic acid in a pharmaceutically acceptable carrier.

8 . The kit of claim 6 wherein the hydrating agent comprises a hyaluronic acid in a pharmaceutically acceptable carrier.

9 . The kit of claim 7 wherein the hydrating agent comprises water, sodium hyaluronate, sodium chloride, sodium monohydrogenphosphate and sodium dihydrogenphosphate.

10 . The kit of claim 8 wherein the hydrating agent comprises water, sodium hyaluronate, sodium chloride, sodium monohydrogenphosphate and sodium dihydrogenphosphate.

11 . The kit of claim 9 wherein the hydrating agent is Viscontour® brand hyaluronic acid serum.

12 . The kit of claim 10 wherein the hydrating agent is Viscontour® brand hyaluronic acid serum.

13 . The kit of claim 12 wherein the topical medication is BenzaClin® brand clindamycin-benzoyl peroxide gel.

14 . A method of treating a skin disorder or condition in a patient, the method comprising topically administering a medication comprising benzoyl peroxide in a pharmaceutically acceptable carrier, and applying a separate hydrating agent to the skin.

15 . The method of claim 14 wherein the medication is topically administered to the skin first and the hydrating agent is applied to the skin second.

16 . The method of claim 14 wherein the medication further comprises an antibiotic.

17 . The method of claim 16 wherein said antibiotic is clindamycin or a pharmaceutically acceptable salt or ester thereof.

18 . The method of claim 17 wherein the antibiotic is clindamycin phosphate.

19 . The method of claim 14 wherein the hydrating agent comprises a hyaluronic acid in a pharmaceutically acceptable carrier.

20 . The method of claim 18 wherein the hydrating agent comprises a hyaluronic acid in a pharmaceutically acceptable carrier.

21 . The method of claims 14 wherein the skin disorder is acne.

22 . The method of claims 20 wherein the skin disorder is acne.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
CHANGE IN NAME AND COUNTRY OF INCORPORATION Recorded Aug 9, 2012
From: VALEANT INTERNATIONAL (BARBADOS) SRL
To: VALEANT INTERNATIONAL BERMUDA
Reel/Frame 028757/0052 →
SECURITY AGREEMENT Recorded Jul 30, 2012
From: VALEANT INTERNATIONAL BERMUDA (FORMERLY KNOWN AS VALEANT INTERNATIONAL (BARBADOS) SRL); VALEANT LABORATORIES INTERNATIONAL BERMUDA (FORMERLY KNOWN AS BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) SRL)
To: GOLDMAN SACHS LENDING PARTNERS LLC
Reel/Frame 028680/0866 →
CHANGE OF NAME Recorded Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2012
From: MONTALVO, MANNY; ROBINETT, JOANNE; WIGLEY, DAVID N.
To: SANOFI-AVENTIS
Reel/Frame 027884/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2012
From: SANOFI
To: VALEANT INTERNATIONAL (BARBADOS) SRL
Reel/Frame 027507/0506 →
CHANGE OF NAME Recorded Sep 15, 2011
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 026913/0092 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2011
From: MONTALVO, MANNY; ROBINETT, JOANNE; WIGLEY, DAVID N.
To: SANOFI-AVENTIS
Reel/Frame 026912/0269 →